The addition of these new drugs swells Aida’s product pipeline from four to seven developmental drugs. The three drugs are either being evaluated for pre-clinical trials or in various early stages of applied research.
The drugs include – Prodigiosin, a naturally occurring red pigment, currently in pre-clinical trials for the treatment of pancreatic cancer, an anti-CD86 monoclonal antibody to treat immune diseases and an anti-CTLA-4 monoclonal antibody to inhibit tumor growth.
“Each of these drugs represents a unique scientific opportunity to improve healthcare for critical patients. Physicians and patients are demanding non-invasive biochemical therapies; Aida Pharmaceuticals has the knowledge and capacity to develop and deliver these therapies over the long-term,” stated Jin Biao, Aida Pharmaceuticals’ chairman.